Last quarter (Q3 2023), BioVaxys Technology's total revenue was C$―, a decrease of ― from the same quarter last year. In Q3, BioVaxys Technology's net income was C$-1.58M. See BioVaxys Technology’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Oct 22	Oct 21	Oct 20	Oct 19	Oct 18
Total Revenue	-	-	-	-	C$ 0.00	C$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	C$ 3.18M	C$ 4.08M	C$ 6.44M	C$ 1.10M	C$ 216.67K	C$ 161.23K
Operating Income	C$ -3.18M	C$ -4.08M	C$ -6.44M	C$ -1.10M	C$ -216.67K	C$ -161.23K
Net Non Operating Interest Income Expense	C$ 13.56K	C$ 15.77K	C$ -7.66K	C$ -137.00	C$ 0.00	-
Other Income Expense	C$ -5.66M	C$ 7.64M	C$ -23.56K	C$ -4.38K	C$ -209.00	-
Pretax Income	C$ -12.57M	C$ -11.73M	C$ -6.46M	C$ -1.10M	C$ -216.88K	C$ -161.23K
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	C$ -12.57M	C$ -11.73M	C$ -6.46M	C$ -1.17M	C$ -230.12K	C$ -161.23K
Basic EPS	C$ -0.03	C$ -0.12	C$ -0.08	C$ -0.04	C$ -0.02	C$ >-0.01
Diluted EPS	C$ -0.03	C$ -0.12	C$ -0.08	C$ -0.04	C$ -0.02	C$ >-0.01
Basic Average Shares	C$ 391.34M	C$ 98.18M	C$ 82.93M	C$ 28.21M	C$ 10.39M	C$ 21.02M
Diluted Average Shares	C$ 391.34M	C$ 98.18M	C$ 82.93M	C$ 28.21M	C$ 10.39M	C$ 21.02M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	C$ 3.18M	C$ 4.08M	C$ -6.44M	C$ -1.10M	C$ 216.67K	C$ 161.23K
Interest Expense	-	-	-	-	-	-
Net Income From Continuing And Discontinued Operation	C$ -12.57M	C$ -11.73M	C$ -6.46M	C$ -1.17M	C$ -230.12K	C$ -161.23K
Normalized Income	C$ -2.34M	C$ -1.22M	C$ -4.75M	C$ -810.43K	C$ -216.67K	C$ -161.23K
EBIT	C$ -4.95M	C$ -11.73M	C$ -6.46M	C$ -1.10M	C$ -216.67K	C$ -161.23K
EBITDA	C$ -3.99M	C$ -11.73M	C$ -6.46M	C$ -1.10M	C$ -216.67K	C$ -161.23K

Currency in CAD

BioVaxys Technology Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing